These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 24648719)
21. Therapeutic potential of prostaglandin analogues in glaucoma. Lindén C Expert Opin Investig Drugs; 2001 Apr; 10(4):679-94. PubMed ID: 11281818 [TBL] [Abstract][Full Text] [Related]
22. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension. Fingeret M; Gaddie IB; Bloomenstein M Clin Exp Optom; 2019 Nov; 102(6):541-550. PubMed ID: 30614563 [TBL] [Abstract][Full Text] [Related]
23. Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Lee AJ; McCluskey P Clin Ophthalmol; 2010 Jul; 4():741-64. PubMed ID: 20689791 [TBL] [Abstract][Full Text] [Related]
24. Intraocular pressure and visual field changes in normal-tension glaucoma patients treated using either unoprostone or latanoprost: a prospective comparative study. Takemoto D; Higashide T; Saito Y; Ohkubo S; Udagawa S; Takeda H; Sugiyama K Clin Ophthalmol; 2017; 11():1617-1624. PubMed ID: 28979091 [TBL] [Abstract][Full Text] [Related]
25. Additive efficacy of unoprostone isopropyl 0.12% (rescula) to latanoprost 0.005%. Stewart WC; Sharpe ED; Stewart JA; Holmes KT; Latham KE Am J Ophthalmol; 2001 Mar; 131(3):339-44. PubMed ID: 11239866 [TBL] [Abstract][Full Text] [Related]
26. An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension. Feldman RM Expert Opin Pharmacother; 2004 Apr; 5(4):909-21. PubMed ID: 15102573 [TBL] [Abstract][Full Text] [Related]
27. Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension. Hoy SM Drugs; 2018 May; 78(7):773-780. PubMed ID: 29761382 [TBL] [Abstract][Full Text] [Related]
28. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension. Aung T; Chew PT; Yip CC; Chan YH; See JL; Khng CG; Hoh ST; Ng LH; Lee HM Am J Ophthalmol; 2001 May; 131(5):636-42. PubMed ID: 11336940 [TBL] [Abstract][Full Text] [Related]
29. Increase in outflow facility with unoprostone treatment in ocular hypertensive patients. Toris CB; Zhan G; Camras CB Arch Ophthalmol; 2004 Dec; 122(12):1782-7. PubMed ID: 15596580 [TBL] [Abstract][Full Text] [Related]
30. Current status of unoprostone for the management of glaucoma and the future of its use in the treatment of retinal disease. Harms NV; Toris CB Expert Opin Pharmacother; 2013 Jan; 14(1):105-13. PubMed ID: 23199345 [TBL] [Abstract][Full Text] [Related]
31. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Ota T; Aihara M; Narumiya S; Araie M Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4159-63. PubMed ID: 16249494 [TBL] [Abstract][Full Text] [Related]
32. Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma. Tamada Y; Taniguchi T; Murase H; Yamamoto T; Kitazawa Y J Ocul Pharmacol Ther; 2001 Feb; 17(1):19-25. PubMed ID: 11322634 [TBL] [Abstract][Full Text] [Related]
33. Effects of TAK-639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice. Millar JC; Savinainen A; Josiah S; Pang IH Exp Eye Res; 2019 Nov; 188():107763. PubMed ID: 31421135 [TBL] [Abstract][Full Text] [Related]
34. The pros and cons of different prostanoids in the medical management of glaucoma. Susanna R; Medeiros FA Curr Opin Ophthalmol; 2001 Apr; 12(2):149-56. PubMed ID: 11224723 [TBL] [Abstract][Full Text] [Related]
35. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension. Kaufman PL Expert Opin Pharmacother; 2017 Mar; 18(4):433-444. PubMed ID: 28234563 [TBL] [Abstract][Full Text] [Related]
36. Prostaglandin analogs in the treatment of glaucoma. Hejkal TW; Camras CB Semin Ophthalmol; 1999 Sep; 14(3):114-23. PubMed ID: 10790575 [TBL] [Abstract][Full Text] [Related]
37. Current status of prostaglandin therapy: latanoprost and unoprostone. Susanna R; Chew P; Kitazawa Y Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S97-104. PubMed ID: 12204705 [TBL] [Abstract][Full Text] [Related]
38. Therapeutic Drugs and Devices for Tackling Ocular Hypertension and Glaucoma, and Need for Neuroprotection and Cytoprotective Therapies. Sharif NA Front Pharmacol; 2021; 12():729249. PubMed ID: 34603044 [TBL] [Abstract][Full Text] [Related]
39. Management of glaucoma: focus on pharmacological therapy. Marquis RE; Whitson JT Drugs Aging; 2005; 22(1):1-21. PubMed ID: 15663346 [TBL] [Abstract][Full Text] [Related]